



DOI: <https://doi.org/10.56936/18290825-3.19v.2025-97>

COVID-19 ASSOCIATED INCRUSTING CYSTITIS: A CASE REPORT

MARTIROSYAN D. A.^{*}, MURADYAN A. A.

Department of Urology and andrology, Yerevan State Medical University, Yerevan, Armenia

Received 24.02.2024; Accepted for printing 15.05.2025

ABSTRACT

On 11.03.2020, the World Health Organization declared the coronavirus disease (COVID-19) caused by the novel coronavirus (SARS CoV-2) a global pandemic. COVID-19 is a potentially severe respiratory infection caused by the SARS CoV-2 pathogen. SARS CoV-2 is an RNA-containing beta coronavirus. SARS-CoV-2 has a unique three-dimensional protein structure characterized by a strong binding affinity for angiotensin-converting enzyme 2 (ACE2) receptors. Under these conditions, human ACE2-producing organs may act as target cells for SARS-CoV-2.

Incrustation cystitis is believed to be a relatively rare complication in COVID-19 patients. The development of bladder lesions may be due to the disruption of blood flow to the bladder wall caused by SARS CoV-2. It is known that COVID-19 infection often causes hypercoagulation, which is accompanied by an increase in blood coagulation factors and endothelial dysfunction. Microcirculatory disturbances probably also play an important role in the pathogenesis of COVID-19-induced incrustation cystitis. The causes of hemodynamic disturbances are not fully understood and may be due to direct viral effects, immune-mediated mechanisms, or a combination of these. It is possible that bladder inflammation is caused by local endopheliitis, which is complicated by thrombosis of vessels of various calibers and increases ischemia of the bladder wall.

This case report of a 76-years-old woman who was hospitalized to the urology department complaining of painful, frequent urination, and blood in the urine. The case report describes the medical history, laboratory and instrumental examinations, surgical intervention, histological examination results, and follow-up of the patient.

Only urine acidification and endoscopic resection of the affected mucosa are considered effective in the treatment of encrusted cystitis. According to the literature, it is desirable that after resection, patients be treated with antibiotics against *C. urealyticum*. It has been established that *C. urealyticum* is sensitive to ofloxacin, norfloxacin and ciprofloxacin, fluoroquinolones, clinafloxacin, gemifloxacin, levofloxacin. Because newer antibiotics such as linezolid and quinupristin-dalfopristin have been shown to be effective in vitro against *C. urealyticum* strains, these antibiotics may prove to be useful alternative glycopeptides in the treatment of *C. urealyticum* infection caused by multidrug-resistant strains.

In conclusion in patients infected with Covid-19, with concomitant signs of urogenital tract infection, in addition to instrumental methods for detecting Incrustation cystitis, bacteriological studies were carried out to determine *C. urealyticum*. After endoscopic resection of the affected mucous membrane, it is advisable to choose a more targeted treatment tactic for *C. urealyticum* infection.

CITE THIS ARTICLE AS:

Martirosyan D. A., Muradyan A. A. (2025). Covid-19 Associated Incrusting Cystitis: A Case Report; The New Armenian Medical Journal, vol.19 (3), 97-101; <https://doi.org/10.56936/18290825-3.19v.2025-97>

ADDRESS FOR CORRESPONDENCE:

Davit A. Martirosyan, MD,
Department of Urology and andrology Yerevan State Medical University after M. Heratsi
2 Koryun Street, Yerevan 0025, Armenia
Tel.: (+374 55) 03-03-93
E-mail: martirosyan_davit@yahoo.com

Introduction

On 11.03.2020, the World Health Organization declared the coronavirus disease (COVID-19) caused by the novel coronavirus (SARS CoV-2) a global pandemic. As of August 6, 2023, there have been more than 769 million confirmed cases of the disease and more than 6.9 million deaths worldwide. Currently reported cases do not accurately represent the level of infection due to reduced testing and reporting worldwide. COVID-19 is now a recognized and ongoing public health problem. It continues to be one of the most important problems in modern medicine [Zou X et al., 2020]. Coronavirus disease (COVID-19) is a potentially severe respiratory infection caused by the SARS CoV-2 pathogen. SARS CoV-2 is an RNA-containing beta coronavirus. It is believed to have originated in bats, but the intermediate link between them and humans has not yet been identified [Feng He et al., 2020]. It is highly contagious, the main routes of transmission are contact and airborne. Aerosols containing the virus, which are produced by coughing or sneezing of infected people, are the main source of infection, and latent transmission can occur from asymptomatic patients [Yongshi Yang et al., 2020]. The incubation period for SARS-CoV-2 ranges from 2-14 days. COVID-19 is a disease that can have a mild or severe course of acute respiratory viral infection, may be accompanied by a number of other symptoms. The pathogenesis of the disease is characterized by the entry of viral particles into the lung endothelial cells by binding to the angiotensin-converting enzyme receptors, which leads to the development of a syndrome of activation of macrophages, natural killer cells, followed by a cytokine storm. A patient with COVID-19 usually has fever (98.6%), fatigue (69.6%), dry cough (59.4%), muscle pain (34.8%), shortness of breath (31.2%), as well as nausea and diarrhea (10.1%) [Desouky E, 2021]. The most common complication of the disease is bilateral viral pneumonia, which in many patients leads to respiratory failure. COVID-19 is multisystemic disease and can lead to damage to almost any organ in the body. The organs of the urinary system are no exception [Lin L et al., 2020]. SARS-CoV-2 has a unique three-dimensional protein structure characterized by a strong binding affinity for angiotensin-converting enzyme 2 (ACE2) receptors.

Under these conditions, human ACE2-producing organs may act as target cells for SARS-CoV-2 [Ling Lin et al., 2020] Zhou and co-authors used a threshold of 1% ACE2-positive cells to identify organs at high risk of viral invasion and reported that the heart, spleen, esophagus, bladder (ACE2-positive cells in the bladder urothelium are 2.4%) and kidneys (ACE2-positive cells in the proximal tubules are 4%) may be target organs at high risk of viral invasion. This may explain the acute kidney injury that occurs in 0.1–29% of COVID-19 patients [Xin Zou et al., 2020].

Incrustation cystitis is believed to be a relatively rare complication in COVID-19 patients. Incrustation cystitis is a rare pathology, the main cause of which is a urinary tract infection, especially with urea-splitting bacteria [Tarun J et al., 2022].

C. urealyticum is a gram-positive bacterium that causes alkalinization of urine by degrading urea to ammonia, which in turn leads to the deposition of calcium phosphate and struvite in the bladder mucosa. The disease is characterized by calcification of the bladder mucosa, which can be diagnosed by instrumental examinations: ultrasound and CT scan, cystoscopy and biopsy. Urine acidification and endoscopic resection of mucosal lesions are effective in treating incrustation cystitis [Puliatti S et al., 2020]. The development of bladder lesions may be due to the disruption of blood flow to the bladder wall caused by SARS CoV-2. It is known that COVID-19 infection often causes hypercoagulation, which is accompanied by an increase in blood coagulation factors and endothelial dysfunction. Microcirculatory disorders and ischemia of the bladder wall are a pathogenic factor and are found in many lower urinary tract pathologies [Al Shukri S et al., 2011]. Microcirculatory disturbances probably also play an important role in the pathogenesis of COVID-19-induced incrustation cystitis. The causes of hemodynamic disturbances are not fully understood and may be due to direct viral effects, immune-mediated mechanisms, or a combination of these. It is possible that bladder inflammation is caused by local endopheliitis, which is complicated by thrombosis of vessels of various calibers and increases ischemia of the bladder wall [Varga Z et al., 2020].

Case Report

A 76-year-old woman was hospitalized in the urology department, complaining of painful, frequent urination, and blood in the urine. The patient had been reporting the above complaints since January 2022, when she was hospitalized due to COVID-19 and had a urinary catheter. The patient did not mention any complaints or pathologies in the urinary system in her anamnesis. About 3 months before hospitalization, the patient had received treatment in the infectious disease department, where she was hospitalized with a diagnosis of COVID-19, interstitial pneumonia of bilateral viral etiology. During treatment, a urinary catheter was inserted, which was removed 10 days later. The patient received antibacterial, anti-inflammatory, hormonal, antiviral, anticoagulant, antihypertensive drugs, insulin and symptomatic therapy. In the urology department, a general urine test revealed 10-15 leukocytes and 2-4 erythrocytes in the field of view. A bacteriological test of urine performed twice did not show any growth of microorganisms, and mycobacterium tuberculosis was not detected. An ultrasound examination revealed thickening of the bladder walls, and a 2.4 cm formation was found on the right wall. An abdominal and pelvic CT scan with intravenous contrast was also performed, which revealed pathological thickening of the anterior and posterior walls of the bladder with incrustations. Taking into account the complaints and the results of instrumental examinations, cystoscopy was performed. During cystos-

copy, the ureteral openings had a typical location, calcified and encrusted areas were visible over the entire surface of the bladder mucosa. Intact areas of the mucosa were present between the calcified, and encrusted areas of the bladder mucosa (white-arrows) (Fig. 1). An transurethral resection of the altered parts of the patient's bladder mucosa was performed, the removed tissue was sent for pathohistological examination (Fig. 2). After the operation, a urinary catheter was placed, an irrigation system was connected. The postoperative period was smooth, without complications, the irrigation system was removed on the second day after surgery, the urinary catheter was removed on the third day after surgery. The patient received appropriate antibacterial and anti-inflammatory therapy in the postoperative period. Pathohistological examination of the examined material revealed a picture of chronic, active cystitis with focal desquamation of the urothelium and foci of necrosis.

Seven months later, the patient was re-admitted to the urology department with the same complaints. A urine test revealed a significant number of erythrocytes in the urine. A bacteriological test of urine performed twice did not show any growth of microorganisms. An abdominal and pelvic CT scan with intravenous contrast was also performed, which revealed pathological thickening of the anterior walls of the bladder. Cystoscopy was performed, during which hyperemia of the bladder mucosa, slightly encrusted, altered areas of the mucosa were detected. This time also transurethral



FIGURE 1. The patient was found to have focally altered, calcified (Выделено кругом), encrusted areas detected during cystoscopy.



FIGURE 2. Bladder after resection. The postoperative period was smooth, without complications.

resection of the altered mucosa was performed, and the removed pieces were sent for pathohistological examination. Pathohistological examination of the examined material revealed the same picture of chronic, active cystitis with focal desquamation of the urothelium and foci of necrosis.

DISCUSSION

C. urealyticum is a gram-positive bacterium that causes alkalization of urine by degrading urea to ammonia, which in turn leads to the deposition of calcium phosphate and struvite in the bladder mucosa. The disease is characterized by calcification of the bladder mucosa [Puliatti S et al., 2020].

The pattern of antimicrobial susceptibility of *C. urealyticum* varies among isolates obtained from different sources [Nieto E et al., 2000]. Most *C. urealyticum* strains obtained from clinical specimens typically exhibit multiple antibiotic resistance [de Briel D et al., 1991, García-Rodríguez J et al., 1991, Funke G, Bernard KA, 2007].

Considering the fact that the patient had signs of urological infection before admission to the infectious diseases department for treatment of COVID-19 infection and was subjected to antimicrobial treatment, and also that most strains of *C. urealyticum* obtained from clinical samples usually demonstrate multiple resistance to antibiotics, it can be assumed that the antibiotics taken did not affect the viability of *C. urealyticum*, which continued to calcify the bladder mucosa [de Briel D et al., 1991, García-Rodríguez J et al., 1991, Funke G, Bernard KA, 2007].

Based on this, only urine acidification and endoscopic resection of the affected mucosa are considered effective in the treatment of encrusted cystitis [Puliatti S et al., 2020], however, in our opinion, they are insufficient for the complete elimination of the disease. According to the literature, it is desirable that after resection, patients be treated with antibiotics against *C. urealyticum*. It has been established that *C. urealyticum* is sensitive to ofloxacin, norfloxacin and ciprofloxacin, fluoroquinolones, clinafloxacin, gemifloxacin, levofloxacin [Santamaría M et al., 1985; Soriano F et al., 1987; Martínez-Martínez L et al., 2001; Sánchez Hernández J et al., 2003]. Because newer antibiotics such as linezolid and quinupristin-dalfopristin have been shown to be effective in vitro against *C. urealyticum* strains, these antibiotics may prove to be useful alternative glycopeptides in the treatment of *C. urealyticum* infection caused by multidrug-resistant strains.

CONCLUSION

Thus, it can be concluded that in patients infected with Covid-19, with concomitant signs of urogenital tract infection, in addition to instrumental methods for detecting encrustation cystitis (calcification of the bladder mucosa), bacteriological studies were carried out to determine *C. urealyticum*. After endoscopic resection of the affected mucous membrane, it is advisable to choose a more targeted treatment tactic for *C. urealyticum* infection.

REFERENCES

1. Al Shukri S.H., Kuzmin I.V., Boriskina A.G., Slesarevskaya M.N., Kyrkunova S.L. (2011) [Correction of microcirculatory disorders in patients with overactive bladder] [Published in Russian] Zhurnal Aktualnie problemi urologii ISSN 15616274. Nefrologiya. 2011. 15. №1.
2. de Briel D, Langs JC, Rougeron G, Chabot P, Le Faou A (1991) .Multiresistant corynebacteria in bacteriuria: a comparative study of the role of Corynebacterium group D2 and Corynebacterium jeikeium; J Hosp Infect, 17 (1991), pp. 35-43
3. Desouky E. (2021). SARS-CoV-2 tropism: what urologists need to know. African Journal of Urology, 2021;27(1):23. <https://doi.org/10.1186/s12301-021-00126-0>
4. Feng He, Yu Deng, Weina Li. (2020). Coronavirus Disease 2019: what we know? Journal Medical Virology, 2020. doi: 10.1002/jmv.25766
5. Funke G, KA Bernard (2007). Coryneform Gram-positive rods PR Murray (Ed.), Manual of clinical microbiology (9th edn.), ASM Press, Washington, DC (2007), pp. 485-514
6. García-Rodríguez JA, García Sánchez JE, Muñoz Bellido, JL Nebreda Mayoral T, García Sánchez E, García García I (1991): In vitro

- activity of 79 antimicrobial agents against Corynebacterium group D2, Antimicrob Agents Chemother, 35 (1991), pp. 2140-2143
7. Lin L., Lu L., Cao W., Li T. (2020). Hypothesis for potential pathogenesis of SARS CoV-2 infection – a review of immune changes in patients with viral pneumonia. *Emerging Microbes and Infections*, 2020;9(1):727 -32. doi: 10.1080/22221751.2020.1746199
8. Ling Lin, Lianfeng Lu, Wei Cao, Taisheng Li. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection– a review of immune changes in patients with viral pneumonia. *Emerging Microbes and Infections* 2020,9(1):727–32. doi: 10.1080/22221751.2020.1746199
9. Martínez-Martínez L, Joyanes P, Suárez AI, Perea EJ (2001). Activities of gemifloxacin and five other antimicrobial agents against *Listeria monocytogenes* and coryneform bacteria isolated from clinical samples, *Antimicrob Agents Chemother*, 45 (2001), pp. 2390-2392
10. Nieto E, Vindel A, Valero-Guillén PL, Saéz-Nieto JA, Soriano F (2000). Biochemical, antimicrobial susceptibility and genotyping studies on *Corynebacterium urealyticum* isolates from diverse sources; *J Med Microbiol*, 49 (2000), pp. 759-763
11. Stefano P, Eissa A, Eissa R, Amato M, Mazzone E, Dell’Oglio P., et al., (2020). . COVID-19 and urology. A comprehensive review of literature. <https://doi.org/10.1111/bju.15071>
12. Sánchez Hernández J, Mora Peris B, Yagüe Guirao G, et al. (2003). In vitro activity of newer antibiotics against *Corynebacterium jeikeium*, *Corynebacterium amycolatum* and *Corynebacterium urealyticum* *Int J Antimicrob Agents*, 22 (2003), pp. 492-496
13. Santamaría M, Ponte C, Wilhelmi I, Soriano F (1985). Antimicrobial susceptibility of *Corynebacterium* group D2 *Antimicrob Agents Chemother*, 28 (1985), pp. 845-846
14. Soriano F, Ponte C, Santamaría M, Torres A, Fernández-Roblas R (1987). Susceptibility of urinary isolates of *Corynebacterium* group D2 to fifteen antimicrobials and acetohydroxamic acid *J Antimicrob Chemother*, 20 (1987), pp. 349-355
15. Soriano F; Tauch A. (2008). Microbiological and clinical features of *Corynebacterium urealyticum*: urinary tract stones and genomics as the Rosetta Stone. , 14(7), 632–643. doi:10.1111/j.1469-0691.2008.02023.x
16. Jindal T, Mukherjee S, (2022). Encrusted cystitis and ascites due to urethral calculus. *Asian Journal of Urology*, V. 9, April 2022. <https://doi.org/10.1016/j.ajur.2021.04.010>
17. Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R. et al. (2020). Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* 2020;395(10234):1417-1418. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5)].
18. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al., (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020. doi: 10.1001/jama.2020.1585
19. Xin Zou, Ke Chen, Jiawei Zou, Peiyi Han, Jie Hao, Zeguang Han(2020). Single-cell RNA seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of Medicine*, 2020;14(2):185-192. doi: 10.1007/s11684-020-0754-0
20. Yongshi Yang, Fujun Peng, Runsheng Wang, Kai Guan, Taijio Jiang, Guogang Xu, et al., (2020). The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. *Journal of Autoimmunity*, 2020, 102434. doi: 10.1016/j.jaut.2020.102434
21. Zou X., Chen K., Zou J., Han P., Hao J., Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers of Medicine* 2020;14(2):185-192. doi: 10.1007/s11684-020-0754-0



CONTENTS

4. **AVAGYAN A.S., MURADYAN A.A., MAKLETSOVA M.G., POLESHCHUK B.B., ZILFYAN A.V.**
THE ROLE OF ALIPHATIC POLYAMINES AND A-SYNUCLEIN IN THE FORMATION OF PERIPHERAL MECHANISMS INVOLVED IN THE PARKINSON'S DISEASE INDUCTION
17. **SHULIATNIKOVA O.A., KARAKULOVA Y.V., BATOG E.I., ROGOZNIKOV G.I.**
STUDY OF THE COMORBID ASSOCIATION OF INFLAMMATORY PERIODONTAL DISEASES AND PATHOLOGY OF THE NERVOUS SYSTEM
23. **BARI MD.N., ANWAR MD., ANSARI MD.R., OSMAN. E.H.A., ALFAKI, M.A., MOHAMMAD I.**
A COMPLICATED SITUATION OF DIAGNOSIS OF BIOMARKERS IN ALCOHOLIC LIVER CIRRHOSIS INJURY BY ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD
30. **GAVANJI S., BAKHTARI A., BAGHSHAHI H., HAMAMI CHAMGORDANI Z., GAVANJI J., SINAIEI J., HASSANI D.**
COMPARING THE ANTI-CANDIDA ALBICANS EFFECT OF ZINGIBER OFFICINALE WITH COMMON ANTIFUNGAL DRUGS
37. **MASNAVI E., HASANZADEH S.**
FREQUENCY OF AMINOGLYCOSIDES RESISTANCE GENES (ANT(4')-IA, APH(3')-IIIA, AAC-(6')-IE-/APH2) IN STAPHYLOCOCCUS AUREUS ISOLATED FROM SURGICAL AND RESPIRATORY SITE INFECTIONS
44. **SHAHSAFI M., MADRNI M., MOHAJERANI H.R., AKBARI M.**
EVALUATION OF THE ANTIBACTERIAL ACTIVITY OF CYNARA SCOLYMUS EXTRACT AND ITS WOUND HEALING POTENCY AGAINST MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII, *In vitro* AND *In Vivo* STUDY
57. **KANANNEJAD Z., HOSSEINI S.F., KARIMPOUR F., TAYLOR W.R., GEVORGIAN L., GHATEE M. A.**
EXPLORING CLIMATIC AND GEOGRAPHICAL DRIVERS OF HEPATITIS B VIRUS SPREAD IN KOHGILUYEH AND BOYER-AHMAD PROVINCE, IRAN
67. **SAMETZADEH M., ROGHANI M., ASKARPOUR S., SHAYESTEZADEH B., HANAFI M.G.**
NON-ENHANCED CT FINDINGS IN PATIENTS SUSPECTED OF ACUTE APPENDICITIS WITH NON-DIAGNOSTIC ULTRASONOGRAPHY
75. **ZHARFAN A.S., AIRLANGGA P.S., SANTOSO K.H., FITRIATI M.**
PERIOPERATIVE MANAGEMENT OF CESAREAN SECTION IN A PATIENT WITH SEVERE SCOLIOSIS: A CASE REPORT
82. **MOHAMMADI ARANI F., SHIRMOHAMMADI M., TAVAKOL Z., KARAMI M., RAEISI SHAHRAKI H., KHALEDIFAR A.**
EFFECTIVENESS OF COGNITIVE BEHAVIORAL THERAPY ON SEXUAL SELF-EFFICACY IN REPRODUCTIVE-AGED WOMEN WITH CARDIOVASCULAR DISEASE (A RANDOMIZED CLINICAL TRIAL STUDY)
91. **MAGHAKYAN S.A., AGHAJANOVA E.M., KHACHATURYAN S.R., HRANTYAN A.M., MELKONYAN N.R., ALEKSANYAN A.Y., BARSEGHYAN E.S., MURADYAN A.A.**
ASSOCIATION OF PRIMARY HYPERPARATHYROIDISM AND PAPILLARY THYROID CARCINOMA IN A PATIENT WITH BROWN TUMOR AND PARKINSONISM: CASE REPORT
97. **MARTIROSYAN D. A., MURADYAN A. A.**
COVID-19 ASSOCIATED INCRUSTING CYSTITIS: A CASE REPORT
102. **FAGHIHRAD H.R., SHEIKHBAGHERI B., ROKNABADI M., SHAPOURI R.**
HERBAL OINTMENT BLEND AND ANTIBACTERIAL ACTIVITY
108. **FANARJYAN R.V., ZAKARYAN A.V., KALASHYAN M.V., ZAKARYAN A.N.**
ACUTE INTRATUMORAL HEMORRHAGE IN A MENINGOTHELIAL MENINGIOMA: A CASE REPORT OF EMERGENCY RESECTION
112. **MKRTCHYAN R.A., GHARDYAN G.K., ABRAHAMYAN L.R., KARALYAN N.YU., ABRAHAMYAN S.H., ABRAHAMYAN R.A.**
SIRENOMELIA: A UNIQUE CONGENITAL ANOMALY (CLINICAL CASE)



The Journal is founded by
Yerevan State Medical
University after M. Heratsi.



Rector of YSMU

Armen A. Muradyan

Address for correspondence:

Yerevan State Medical University
2 Koryun Street, Yerevan 0025,
Republic of Armenia

Phones:

(+37410) 582532 YSMU

(+37493 588697 Editor-in-Chief

Fax: (+37410) 582532

E-mail: namj.ysmu@gmail.com, ysmiu@mail.ru

URL: <http://www.ysmu.am>

Our journal is registered in the databases of Scopus,
EBSCO and Thomson Reuters (in the registration process)



SCOPUS



EBSCO

REUTERS

Copy editor: Kristina D Matevosyan

LLC Print in "Monoprint" LLC

Director: Armen Armenakyan
Andraniks St., 96/8 Bulding
Yerevan, 0064, Armenia
Phone: (+37491) 40 25 86
E-mail: monoprint1@mail.ru

Editor-in-Chief

Arto V. Zilfyan (Yerevan, Armenia)

Deputy Editors

Hovhannes M. Manvelyan (Yerevan, Armenia)

Hamayak S. Sisakyan (Yerevan, Armenia)

Executive Secretary

Stepan A. Avagyan (Yerevan, Armenia)

Editorial Board

Armen A. Muradyan (Yerevan, Armenia)

Drastamat N. Khudaverdyan (Yerevan, Armenia)

Suren A. Stepanyan (Yerevan, Armenia)

Foregin Members of the Editorial Board

Carsten N. GUTT (Memmingen, Germany)

Muhammad MIFTAHUSSURUR (Indonesia)

Alexander WOODMAN (Dharhan, Saudi Arabia)

Coordinating Editor (for this number)

Hesam Adin Atashi (Tehran, Iran)

Editorial Advisory Council

Mahdi Esmaeilzadeh (Mashhad, Iran)

Ara S. Babloyan (Yerevan, Armenia)

Ines Banjari (Osijek, Croatia)

Mariam R Movsisyan (Gymri, Armenia) Azat

A. Engibaryan (Yerevan, Armenia) Ruben V.

Fanarjyan (Yerevan, Armenia) Gerasimos

Filippatos (Athens, Greece) Gabriele Fragasso
(Milan, Italy)

Samvel G. Galstyan (Yerevan, Armenia)

Arthur A. Grigorian (Macon, Georgia, USA)

Armen Dz. Hambardzumyan (Yerevan, Armenia)

Seyran P. Kocharyan (Yerevan, Armenia)

Aleksandr S. Malayan (Yerevan, Armenia)

Mikhail Z. Narimanyan (Yerevan, Armenia)

Yumei Niu (Harbin, China)

Linda F. Noble-Haeusslein (San Francisco, USA)

Arthur K. Shukuryan (Yerevan, Armenia)

Levon M. Mkrtchyan (Yerevan, Armenia)

Gevorg N. Tamamyanyan (Yerevan, Armenia)

Hakob V. Topchyan (Yerevan, Armenia)

Alexander Tsiskaridze (Tbilisi, Georgia)

Konstantin B. Yenkovyan (Yerevan, Armenia)

Peijun Wang (Harbin, China)